95143045 Quality of life during sequential hormone replacement therapy—A placebo-controlled study

Derman, Richard; Dawood, Maha; Stone, Sophia

doi:10.1016/0378-5122(95)99353-4

Cited by 23 publications

(34 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…therapy. Previous studies showed the efficacy of both traditionally prescribed and low-dose estrogen/progestogen regimens in improving quality-of-life rating scales, including the Kupperman index, the Greene index, the WHQ and the Beck Depression Inventory [20][21][22][23]. The results reported in these studies are similar to those observed here in the 17b-E 2 /TMG and E 2 V/NET treatment groups.…”

Section: Discussionsupporting

confidence: 92%

See 1 more Smart Citation

A study of the control of climacteric symptoms in postmenopausal women following sequential regimens of 1 mg 17β-estradiol and trimegestone compared with a regimen containing 1 mg estradiol valerate and norethisterone over a 2-year period

Pornel¹,

Spielmann

2005

Gynecological Endocrinology

View full text Add to dashboard Cite

A study of the control of climacteric symptoms in postmenopausal women following sequential regimens of 1 mg 17b b-estradiol and trimegestone compared with a regimen containing 1 mg estradiol valerate and norethisterone over a 2-year period Abstract Objective. To compare the efficacy of two sequential 17b-estradiol (17b-E 2 )/trimegestone (TMG) combinations with the sequential estradiol valerate (E 2 V)/norethisterone (NET) regimen in relieving climacteric symptoms. Study design. This was a double-blind, randomized, multicenter study conducted among 1218 Caucasian (99%) postmenopausal women with an intact uterus in seven European countries and Israel, over 13 cycles (each of 28 days). Study duration was extended further for 13 cycles, with 531 women receiving treatment for up to 26 cycles. Treatments consisted of 1 mg 17b-E 2 on days 1-14 and 1 mg 17b-E 2 /0.125 mg TMG or 0.25 mg TMG on days 15-28, and 1 mg E 2 V on days 1-16 and 1 mg E 2 V/1 mg NET on days 17-28. Results. Rapid and significant reductions in the mean daily number and severity of hot flushes and in the mean daily number of nocturnal sweats were established in most women with 1 mg 17b-E 2 /0.25 mg TMG and E 2 V/NET. These treatments also induced a significant improvement in the quality-of-life assessments. Conclusion. The 1 mg 17b-E 2 /0.25 mg TMG regimen provides rapid and effective relief of menopausal symptoms, with a reduction in the number of hot flushes 'at least as good as' that of the E 2 V/NET comparator.

show abstract

Section: Discussionsupporting

confidence: 92%

“…The efficacy of the 1 mg 17b-E 2 /0.25 mg TMG combination in reducing vasomotor symptoms was 'at least as good as' that of the 1 mg E 2 V/1 mg NET comparator. This efficacy was similar to that reported for other lower-dose HRT regimens, such as the sequential combination of 1 mg 17b-E 2 and 0.25 mg NETA [20,21].…”

Section: Discussionsupporting

confidence: 82%

A study of the control of climacteric symptoms in postmenopausal women following sequential regimens of 1 mg 17β-estradiol and trimegestone compared with a regimen containing 1 mg estradiol valerate and norethisterone over a 2-year period

Pornel¹,

Spielmann

2005

Gynecological Endocrinology

View full text Add to dashboard Cite

show abstract

“…Clinical studies indicate that estrogen replacement improves mood and increases the sense of well-being in post-menopausal women with no or mild depressive symptoms. However, in postmenopausal women with major depression, estrogen alone is not sufficient, although it may be useful as an augmentation strategy (Derman et al, 1995). Interestingly, estrogen can remedy the symptoms of perimenopausal depression providing support for the idea that ovarian hormones are involved in the expression of the disorder Burt et al, 1998).…”

Section: Estrogen and The Treatment Of Female Depressionmentioning

confidence: 99%

Estrogen-mediated effects on depression and memory formation in females

Shors

Leuner

2003

Journal of Affective Disorders

156

View full text Add to dashboard Cite

Women are twice as likely to suffer from depression as men. It has been proposed that the ovarian hormones estrogen and progesterone contribute to the higher incidence of this potentially debilitating disorder. Depression can also be accompanied by a loss of cognitive performance. Here we review estrogen-mediated effects on depression and memory formation in females. We propose that changes in levels of estrogen are associated with sex differences in learning as well as changes in affect prior to menses, immediately after pregnancy and during perimenopause and the menopausal transition. Finally, we discuss the animal model of depression known as 'learned helplessness' and describe research from our laboratory demonstrating that exposure to an acute stressful experience compromises a female's later ability to acquire certain types of new memories. This response to stressful experience is opposite to that observed in males and is dependent on the presence of estrogen, and more specifically-changing levels of estrogen. This observation indicates that females and males can use different hormonal and neural mechanisms to respond to the same emotional event and underscore the importance of studying the unique and changing biology of females, especially when considering treatment strategies for depression and stress-related illness.

show abstract

“…In naturally menopausal women, placebo-controlled trials of HRT have demonstrated improved mood (e.g., Derman, Dawood, & Stone, 1995;Purdie, Empson, Crichton, & MacDonald, 1995;Klaiber, Broverman, Vogel, Peterson, & Snyder, 1997;Sherwin & Gelfand, 1985). In contrast, Girdler et al (1999) and Hayes et al (2003) concluded that HRT was not associated with changes in mood for naturally menopausal women.…”

mentioning

confidence: 88%

The effect of hormone replacement therapy on mood and everyday memory in younger mid-life women

Stephens

Pachana

Bristow

2006

Psychology, Health & Medicine

View full text Add to dashboard Cite

Research on the effect of hormone replacement therapy (HRT) on both mood and memory indicates that oestrogen may enhance verbal memory in younger mid-aged women. This study examined the effect of HRT on everyday memory, while accounting for mood changes, in women between ages 40 and 60. A within-subjects comparison of 17 women, showed that mood, everyday memory, working memory, and delayed verbal memory improved after 3 months of HRT use. The improvement in memory was not mediated by mood, but changes in mood were moderated by exercise habits. The results suggest that verbal memory in particular may be enhanced by HRT in this age group, and everyday memory is an important construct to consider in future research.

show abstract

95143045 Quality of life during sequential hormone replacement therapy—A placebo-controlled study

Cited by 23 publications

References 0 publications

A study of the control of climacteric symptoms in postmenopausal women following sequential regimens of 1 mg 17β-estradiol and trimegestone compared with a regimen containing 1 mg estradiol valerate and norethisterone over a 2-year period

A study of the control of climacteric symptoms in postmenopausal women following sequential regimens of 1 mg 17β-estradiol and trimegestone compared with a regimen containing 1 mg estradiol valerate and norethisterone over a 2-year period

Estrogen-mediated effects on depression and memory formation in females

The effect of hormone replacement therapy on mood and everyday memory in younger mid-life women

Contact Info

Product

Resources

About